Clinical trials: Proliferative Diabetic Retinopathy (PDR)
Diabetes Mellitus
Fovea Sparing ILM Peeling in Diabetic Patients
The goal of this clinical trial is to compare between foveal sparing ILM peeling and total ILM peeling in diabetic patients (both type 1 and II) with proliferative diabetic retinopathy (PDR) indicated for pars plana vitrectomy…
- Trial name
- NCT07271719
- Testing
- Pars plana vitrectomy (PPV) with fovea sparing ILM peeling., PPV with total ILM peeling
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- David Nashaat Shafik Fahmy
Proliferative Diabetic Retinopathy (PDR)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
The present study is intended to evaluate the efficacy and safety of topical OC-10X Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level 61, 65, 71, or 75). OcuCure Therapeutics, Inc.
- Trial name
- NCT02735369
- Testing
- 2% OC-10X
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- OcuCure Therapeutics, Inc.
Proliferative Diabetic Retinopathy
The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR
Aflibercept, a recombinant fusion antibody that binds to all subtypes of VEGF and PlGF, has been shown to induce effective regression of retinal neovascularization secondary to PDR but there had been lack of a well-structured…
- Trial name
- NCT05478967
- Testing
- IVA injection before vitrectomy
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Peking University People's Hospital
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
Patients with proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring surgical intervention will receive a pre-operative injection of Macugen.
- Trial name
- PEGAP001 (NCT00446381)
- Testing
- Macugen (pegaptanib)
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
To investigate ranibizumab's benefit on prevention of early postoperative vitreous haemorrhage in PDR-DME patients receiving vitrectomy.
- Trial name
- NCT04464694
- Testing
- Ranibizumab, Pars plana vitrectomy
- Where
- 3 sites in China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Proliferative Diabetic Retinopathy, VEGF Overexpression
Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)
Patients with proliferative diabetic retinopathy requiring surgical intervention will receive a pre-operative injection of Conbercept.
- Trial name
- CONCEPT (NCT03506750)
- Testing
- IVC, Blood and aqueous humor at the time of IVC, Collect blood, aqueous humor, and initial vitreous at the time of surgery.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diabetic Retinopathy, Macular Edema
ILM Peeling in PDR Patients Undergoing PPV for VH
Subjects undergoing ILM peeling during vitrectomy will have better visual acuity and lower rates of DME to control subjects
- Trial name
- NCT03660371
- Testing
- PPV/MP, PPV without MP
- Where
- Mexico
- Volunteers
- 258 people
- Sponsor
- Rush Eye Associates
Proliferative Diabetic Retinopathy (PDR)
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
- Trial name
- HERO (NCT07118670)
- Testing
- Aflibercept 8mg
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Edward Wood, MD
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Proliferative Diabetic Retinopathy
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR.
- Trial name
- aiRTo-PDR (NCT02447185)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- JUNYAN ZHANG
Proliferative Diabetic Retinopathy
Safety and Efficacy of Low-Fluence PRP for PDR
To determine the safety and efficacy of a single session of low-fluence panretinal photocoagulation when compared to full-fluence PRP.
- Trial name
- NCT01737957
- Testing
- Low-fluence PRP with 532nm green LASER, Full-Fluence PRP with 532nm LASER
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Proliferative Diabetic Retinopathy, PDR
The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study (TREAT)
Background Diabetic eye disease is the most frequent complication among the 320,000 Danes with diabetes. The formation of new vessels (PDR) in the inner part of the eye (retina) is a feared complication and a leading cause of…
- Conditions
- Proliferative Diabetic Retinopathy, PDR, Diabetes
- Trial name
- NCT03113006
- Testing
- Panretinal Photocoagulation
- Where
- Denmark
- Volunteers
- 53 people
- Sponsor
- Odense University Hospital
Diabetic Retinopathy
ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR
Purpose: To compare panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) and retinal photocoagulation targeted to ischemic retina combined with…
- Trial name
- NCT03904056
- Testing
- ISQ-RP, ETDRS-PRP group
- Volunteers
- 23 people
- Sponsor
- São Paulo State University
Proliferative Diabetic Retinopathy (PDR)
Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy
To evaluate the effects of PRP as monotherapy or with combination of intravitreal Ranibizumab injection on microvascular density changes of the macula of eyes with PDR using OCTA
- Trial name
- PRP VS PRP&RZB (NCT07819253)
- Testing
- Ranibizumab 0.5 mg, laser photocoagulation (PRP)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Aswan University
Proliferative Diabetic Retinopathy, Photocoagulation Burn to Retina
New Pattern of Retinal Laser Treatment for PDR
The objective of the study is to evaluate the efficacy of a new pattern of argon-laser in treating patients with proliferative diabetic retinopathy (PDR).
- Trial name
- NCT07315802
- Testing
- A new pattern of retinal laser
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Proliferative Diabetic Retinopathy
Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at…
- Trial name
- LASERLESS (NCT02976012)
- Testing
- Aflibercept, Endolaserless Vitrectomy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of…
- Trial name
- NCT01069341
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
Corneal Endothelial Cell Changes in Diabetic Patients
Specular Microscopy in Patients With Proliferative Diabetic Retinopathy
.1. corneal endothelial profile in patients with proliferative diabetic retinopathy compared to a healthy age-matched control group. 2. The effect of the age, and duration of Diabetes on the corneal endothelium .
- Trial name
- NCT05838898
- Testing
- Specular microscopy
- Volunteers
- 60 people
- Sponsor
- Assiut University
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals